Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
Quantity Discount Table - Order More To Get More Price Discount
| Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 5 | $238.00 | Total: $1,190.00 |
| 1 | 10 | $201.60 | Total: $2,016.00 |
| 1 | 25 | $170.80 | Total: $4,270.00 |
| 1 | 50 | $145.60 | Total: $7,280.00 |
| 1 | 100 | $126.00 | Total: $12,600.01 |
Overview
CDK461 Inhibitor (Crozbaciclib) is a type of CDK46 inhibitor (IC50s: 3 and 1 nM). CDK46 inhibitor is a class of compounds used for the treatment of some types of hormone receptor positive, HER2-negative breast cancer, which can block the process of breast cancer cell division and reproduction.
Chemical Properties
| Molecular Formula | C28H30F2N6 |
| Molecular Weight | 488.57 |
| CAS Numbers | 2099128-41-1 |
| Solubility | DMSO |
| Purity | 98% by HPLC |
| SMILES Code | CC=1C2(C=3C(N1)=C(F)C=C(C3)C4=NC(NC5=CC=C(C=N5)C6CCN(C)CC6)=NC=C4F)CCCC2 |
Storage and Handling
0C Short Term, -20C Long Term
References
Yin L, et al. A highly potent CDK46 inhibitor was rationally designed to overcome blood brain barrier in gliobastoma therapy. Eur J Med Chem. 2018;144 1-28.